vs
INVO Fertility, Inc.(IVF)与Rigetti Computing, Inc.(RGTI)财务数据对比。点击上方公司名可切换其他公司
Rigetti Computing, Inc.的季度营收约是INVO Fertility, Inc.的1.1倍($1.9M vs $1.8M),INVO Fertility, Inc.净利率更高(-150.5% vs -974.7%,领先824.2%),INVO Fertility, Inc.同比增速更快(22.6% vs -17.9%),INVO Fertility, Inc.自由现金流更多($-1.8M vs $-19.5M),过去两年INVO Fertility, Inc.的营收复合增速更高(12.8% vs -21.8%)
INVO Fertility是一家专注于辅助生殖医疗解决方案的企业,核心产品为专利INVOcell阴道内培养装置,服务北美、欧洲等地区的生殖诊所与患者,致力于降低生育治疗门槛,为有需求的群体提供可负担的生殖医疗服务。
Rigetti Computing总部位于美国加利福尼亚州伯克利,是专业的超导量子集成电路研发商,产品主要应用于量子计算机领域。公司还推出了名为Forest的云平台,支持开发者编写各类量子算法。
IVF vs RGTI — 直观对比
营收规模更大
RGTI
是对方的1.1倍
$1.8M
营收增速更快
IVF
高出40.5%
-17.9%
净利率更高
IVF
高出824.2%
-974.7%
自由现金流更多
IVF
多$17.7M
$-19.5M
两年增速更快
IVF
近两年复合增速
-21.8%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | ||
|---|---|---|
| 营收 | $1.8M | $1.9M |
| 净利润 | $-2.6M | $-18.2M |
| 毛利率 | — | 34.9% |
| 营业利润率 | -93.1% | -1209.7% |
| 净利率 | -150.5% | -974.7% |
| 营收同比 | 22.6% | -17.9% |
| 净利润同比 | -62.2% | 88.1% |
| 每股收益(稀释后) | $-0.77 | $-0.08 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比,按日历期对齐,财年错位的公司也能正确匹配
营收
IVF
RGTI
| Q4 25 | — | $1.9M | ||
| Q3 25 | $1.8M | $1.9M | ||
| Q2 25 | $1.9M | $1.8M | ||
| Q1 25 | $1.6M | $1.5M | ||
| Q4 24 | $1.7M | $2.3M | ||
| Q3 24 | $1.4M | $2.4M | ||
| Q2 24 | $1.8M | $3.1M | ||
| Q1 24 | $1.6M | $3.1M |
净利润
IVF
RGTI
| Q4 25 | — | $-18.2M | ||
| Q3 25 | $-2.6M | $-201.0M | ||
| Q2 25 | $-5.3M | $-39.7M | ||
| Q1 25 | $-17.4M | $42.6M | ||
| Q4 24 | $-3.6M | $-153.0M | ||
| Q3 24 | $-1.6M | $-14.8M | ||
| Q2 24 | $-2.2M | $-12.4M | ||
| Q1 24 | $-1.6M | $-20.8M |
毛利率
IVF
RGTI
| Q4 25 | — | 34.9% | ||
| Q3 25 | — | 20.7% | ||
| Q2 25 | — | 31.4% | ||
| Q1 25 | 35.2% | 30.0% | ||
| Q4 24 | 41.4% | 44.1% | ||
| Q3 24 | 31.0% | 50.6% | ||
| Q2 24 | 53.1% | 64.5% | ||
| Q1 24 | 45.3% | 49.1% |
营业利润率
IVF
RGTI
| Q4 25 | — | -1209.7% | ||
| Q3 25 | -93.1% | -1055.4% | ||
| Q2 25 | -160.4% | -1103.9% | ||
| Q1 25 | -1042.1% | -1469.6% | ||
| Q4 24 | -202.0% | -813.3% | ||
| Q3 24 | -90.7% | -729.4% | ||
| Q2 24 | -100.9% | -521.2% | ||
| Q1 24 | -95.7% | -543.4% |
净利率
IVF
RGTI
| Q4 25 | — | -974.7% | ||
| Q3 25 | -150.5% | -10321.9% | ||
| Q2 25 | -283.6% | -2201.8% | ||
| Q1 25 | -1060.1% | 2895.3% | ||
| Q4 24 | -211.3% | -6726.5% | ||
| Q3 24 | -113.8% | -623.8% | ||
| Q2 24 | -122.2% | -402.5% | ||
| Q1 24 | -101.3% | -680.6% |
每股收益(稀释后)
IVF
RGTI
| Q4 25 | — | $-0.08 | ||
| Q3 25 | $-0.77 | $-0.62 | ||
| Q2 25 | $-13.30 | $-0.13 | ||
| Q1 25 | $-12.53 | $0.13 | ||
| Q4 24 | $14.86 | $-0.80 | ||
| Q3 24 | $-15.11 | $-0.08 | ||
| Q2 24 | $-22.39 | $-0.07 | ||
| Q1 24 | $-7.55 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | ||
|---|---|---|
| 现金及短期投资手头流动性 | — | $44.9M |
| 总债务越低越好 | $2.0M | — |
| 股东权益账面价值 | $5.8M | $546.2M |
| 总资产 | $18.8M | $666.6M |
| 负债/权益比越低杠杆越低 | 0.34× | — |
8季度趋势,按日历期对齐
现金及短期投资
IVF
RGTI
| Q4 25 | — | $44.9M | ||
| Q3 25 | — | $26.1M | ||
| Q2 25 | — | $57.2M | ||
| Q1 25 | — | $37.2M | ||
| Q4 24 | — | $67.7M | ||
| Q3 24 | — | $20.3M | ||
| Q2 24 | — | $20.7M | ||
| Q1 24 | — | $35.1M |
总债务
IVF
RGTI
| Q4 25 | — | — | ||
| Q3 25 | $2.0M | — | ||
| Q2 25 | $4.8M | — | ||
| Q1 25 | — | — | ||
| Q4 24 | $7.5M | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益
IVF
RGTI
| Q4 25 | — | $546.2M | ||
| Q3 25 | $5.8M | $371.8M | ||
| Q2 25 | $2.6M | $553.3M | ||
| Q1 25 | $3.3M | $207.1M | ||
| Q4 24 | $12.7M | $126.6M | ||
| Q3 24 | $-23.3K | $122.8M | ||
| Q2 24 | $1.4M | $122.2M | ||
| Q1 24 | $10.2K | $115.6M |
总资产
IVF
RGTI
| Q4 25 | — | $666.6M | ||
| Q3 25 | $18.8M | $630.3M | ||
| Q2 25 | $19.3M | $636.7M | ||
| Q1 25 | $31.7M | $269.1M | ||
| Q4 24 | $46.4M | $284.8M | ||
| Q3 24 | $17.0M | $157.3M | ||
| Q2 24 | $17.8M | $162.4M | ||
| Q1 24 | $17.3M | $162.1M |
负债/权益比
IVF
RGTI
| Q4 25 | — | — | ||
| Q3 25 | 0.34× | — | ||
| Q2 25 | 1.83× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | 0.59× | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | ||
|---|---|---|
| 经营现金流最新季度 | $-1.8M | $-14.9M |
| 自由现金流经营现金流 - 资本支出 | $-1.8M | $-19.5M |
| 自由现金流率自由现金流/营收 | -101.6% | -1042.5% |
| 资本支出强度资本支出/营收 | 0.5% | 244.8% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $-7.8M | $-77.2M |
8季度趋势,按日历期对齐
经营现金流
IVF
RGTI
| Q4 25 | — | $-14.9M | ||
| Q3 25 | $-1.8M | $-13.8M | ||
| Q2 25 | $-1.7M | $-16.2M | ||
| Q1 25 | $-3.5M | $-13.7M | ||
| Q4 24 | $-617.4K | $-8.5M | ||
| Q3 24 | $-640.8K | $-15.4M | ||
| Q2 24 | $-1.5M | $-13.5M | ||
| Q1 24 | $-260.6K | $-13.1M |
自由现金流
IVF
RGTI
| Q4 25 | — | $-19.5M | ||
| Q3 25 | $-1.8M | $-19.7M | ||
| Q2 25 | $-1.7M | $-21.8M | ||
| Q1 25 | $-3.6M | $-16.2M | ||
| Q4 24 | $-696.3K | $-9.8M | ||
| Q3 24 | — | $-17.7M | ||
| Q2 24 | $-1.5M | $-15.6M | ||
| Q1 24 | $-310.3K | $-18.6M |
自由现金流率
IVF
RGTI
| Q4 25 | — | -1042.5% | ||
| Q3 25 | -101.6% | -1012.4% | ||
| Q2 25 | -92.6% | -1212.4% | ||
| Q1 25 | -216.9% | -1100.4% | ||
| Q4 24 | -40.6% | -432.1% | ||
| Q3 24 | — | -744.5% | ||
| Q2 24 | -82.3% | -504.3% | ||
| Q1 24 | -19.7% | -610.5% |
资本支出强度
IVF
RGTI
| Q4 25 | — | 244.8% | ||
| Q3 25 | 0.5% | 302.5% | ||
| Q2 25 | 0.5% | 314.7% | ||
| Q1 25 | 0.9% | 173.0% | ||
| Q4 24 | 4.6% | 56.4% | ||
| Q3 24 | 0.0% | 95.8% | ||
| Q2 24 | 3.0% | 66.3% | ||
| Q1 24 | 3.2% | 180.0% |
现金转化率
IVF
RGTI
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | -0.32× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
IVF
暂无分部数据
RGTI
| Collaborative Research And Other Professional Services | $1.7M | 93% |
| Other | $131.0K | 7% |